Suppr超能文献

大肠杆菌O157:H7感染期间的相对肾脏保护作用:与静脉补液扩容的关系

Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.

作者信息

Ake Julie A, Jelacic Srdjan, Ciol Marcia A, Watkins Sandra L, Murray Karen F, Christie Dennis L, Klein Eileen J, Tarr Phillip I

机构信息

Department of Medicine, Madigan Army Medical Center, Tacoma, Washington, USA.

出版信息

Pediatrics. 2005 Jun;115(6):e673-80. doi: 10.1542/peds.2004-2236.

Abstract

OBJECTIVE

The hemolytic uremic syndrome (HUS) consists of hemolytic anemia, thrombocytopenia, and renal failure. HUS is often precipitated by gastrointestinal infection with Shiga toxin-producing Escherichia coli and is characterized by a variety of prothrombotic host abnormalities. In much of the world, E coli O157:H7 is the major cause of HUS. HUS can be categorized as either oligoanuric (which probably signifies acute tubular necrosis) or nonoligoanuric. Children with oligoanuric renal failure during HUS generally require dialysis, have more complicated courses, and are probably at increased risk for chronic sequelae than are children who experience nonoligoanuric HUS. Oligoanuric HUS should be avoided, if possible. The presentation to medical care of a child with definite or possible E coli O157:H7 infections but before HUS ensues affords a potential opportunity to ameliorate the course of the subsequent renal failure. However, it is not known whether events that occur early in E coli O157:H7 infections, particularly measures to expand circulating volume, affect the likelihood of experiencing oligoanuric HUS if renal failure develops. We attempted to assess whether pre-HUS interventions and events, especially the volume and sodium content of intravenous fluids administered early in illness, affect the risk for developing oligoanuric HUS after E coli O157:H7 infections.

METHODS

We performed a prospective cohort study of 29 children with HUS that was confirmed microbiologically to be caused by E coli O157:H7. Infected children were enrolled when they presented with acute bloody diarrhea or as contacts of patients who were known to be infected with E coli O157:H7, or if they had culture-confirmed infection, or if they presented with HUS. HUS was defined as hemolytic anemia (hematocrit <30%, with fragmented erythrocytes on peripheral-blood smear), thrombocytopenia (platelet count of <150000/mm3), and renal insufficiency (serum creatinine concentration that exceeded the upper limit of normal for age). A wide range of pre-HUS variables, including demographic factors, clinical history, medications given, initial laboratory values, and volume and content of parenteral fluid administered, were recorded and entered into analysis. Estimates of odds ratios were adjusted for possible confounding effects using logistic regression analysis. Twenty-nine children who were <10 years old, had HUS confirmed to be caused by E coli O157:H7, and were hospitalized at the Children's Hospital and Regional Medical Center, Seattle, were studied. The main outcome measured was development of oligoanuric renal failure. Oligoanuria was defined as a urine output <0.5 mL/kg per hour for at least 24 consecutive hours.

RESULTS

As a group, the children with oligoanuric renal failure presented to medical attention and were evaluated with laboratory testing later than the children with nonoligoanuric renal failure. On initial assessments, the children with oligoanuric outcomes had higher white blood cell counts, lower platelet counts and hematocrits, and higher creatinine concentrations than the children with nonoligoanuric outcomes, but these determinations probably reflect later points of these initial determinations, often when HUS was already developing. Stool cultures were obtained (medians of 3 vs 2 days, respectively) and positive (medians of 7 vs 4 days, respectively) at later points in illness in the children in the oligoanuric than in the nonoligoanuric group. Intravenous volume expansion began later in illness in the children who subsequently developed oligoanuric renal failure than in those whose renal failure was nonoligoanuric (medians: 4.5 vs 3.0 days, respectively). Moreover, the 13 patients with nonoligoanuric renal failure received more intravenous fluid and sodium before HUS developed (1.7- and 2.5-fold differences, respectively, between medians) than the 16 patients with oligoanuric renal failure. These differences were even greater when the first 4 days of illness were examined, with 17.1- and 21.8-fold differences, respectively, between medians. In a multivariate analysis adjusted for age, gender, antibiotic use, and free water volume administered intravenously to these children during the first 4 days of illness, the amount of sodium infused remained associated with protection against developing oligoanuric HUS. Dialysis was used in each of the children with oligoanuric renal failure and in none of the children with nonoligoanuric renal failure. The median length of stay in hospital after the diagnosis of HUS was 12 days in the oligoanuric group and 6 days in the nonoligoanuric group.

CONCLUSIONS

Early recognition of and parenteral volume expansion during E coli O157:H7 infections, well before HUS develops, is associated with attenuated renal injury failure. Parenteral hydration in children who are possibly infected with E coli O157:H7, at the time of presentation with bloody diarrhea and in advance of culture results, is a practice that can accelerate the start of volume expansion during the important pre-HUS interval. Rapid assessment of stools for E coli O157:H7 by microbiologists and reporting of presumptive positives immediately can alert practitioners that patients are at risk for developing HUS and can prompt volume expansion in children who are not already being so treated. Our data also suggest that isotonic intravenous solutions might be superior to hypotonic fluids for use as maintenance fluids. Children who are infected with E coli O157:H7 and are given intravenous volume expansion need careful monitoring. This monitoring should be even more assiduous as HUS evolves.

摘要

目的

溶血尿毒综合征(HUS)包括溶血性贫血、血小板减少和肾衰竭。HUS常由产志贺毒素大肠杆菌的胃肠道感染引发,其特征为多种促血栓形成的宿主异常。在世界上许多地区,大肠杆菌O157:H7是HUS的主要病因。HUS可分为少尿型(可能意味着急性肾小管坏死)或非少尿型。与经历非少尿型HUS的儿童相比,HUS期间出现少尿型肾衰竭的儿童通常需要透析,病程更复杂,慢性后遗症风险可能更高。若可能,应避免少尿型HUS。在明确或可能感染大肠杆菌O157:H7但尚未发生HUS的儿童就医时,有潜在机会改善随后肾衰竭的病程。然而,尚不清楚大肠杆菌O157:H7感染早期发生的事件,尤其是扩充循环血容量的措施,若发生肾衰竭,是否会影响出现少尿型HUS的可能性。我们试图评估HUS前的干预措施和事件,尤其是疾病早期给予的静脉输液量和钠含量,是否会影响大肠杆菌O157:H7感染后发生少尿型HUS的风险。

方法

我们对29例经微生物学确诊由大肠杆菌O157:H7引起的HUS儿童进行了前瞻性队列研究。感染儿童在出现急性血性腹泻时、作为已知感染大肠杆菌O157:H7患者的接触者、或有培养确诊感染、或出现HUS时纳入研究。HUS定义为溶血性贫血(血细胞比容<30%,外周血涂片可见破碎红细胞)、血小板减少(血小板计数<150000/mm3)和肾功能不全(血清肌酐浓度超过年龄正常上限)。记录了广泛的HUS前变量,包括人口统计学因素、临床病史、给予的药物、初始实验室值以及胃肠外补液的量和成分,并进行分析。使用逻辑回归分析对可能的混杂效应进行比值比估计的调整。研究了29例年龄<10岁、确诊由大肠杆菌O157:H7引起HUS且在西雅图儿童医院和地区医疗中心住院的儿童。主要测量结局是少尿型肾衰竭的发生。少尿定义为连续至少24小时尿量<0.5 mL/kg每小时。

结果

总体而言,与非少尿型肾衰竭儿童相比,少尿型肾衰竭儿童就医并接受实验室检查的时间更晚。在初始评估时,少尿型结局的儿童白细胞计数更高,血小板计数和血细胞比容更低,肌酐浓度更高,但这些测定结果可能反映了这些初始测定的较晚时间点,通常是在HUS已经发生时。少尿型组儿童在疾病后期进行粪便培养(中位数分别为3天和2天)且培养结果呈阳性(中位数分别为7天和4天)的时间比非少尿型组更晚。随后发生少尿型肾衰竭的儿童静脉补液扩容开始时间比非少尿型肾衰竭儿童更晚(中位数分别为4.5天和3.0天)。此外,13例非少尿型肾衰竭患者在HUS发生前接受的静脉补液和钠比16例少尿型肾衰竭患者更多(中位数之间分别相差1.7倍和2.5倍)。当检查疾病的前4天时,这些差异更大,中位数之间分别相差17.1倍和21.8倍。在对年龄、性别、抗生素使用以及疾病前4天静脉给予这些儿童的游离水量进行调整的多变量分析中,输注的钠量仍与预防少尿型HUS相关。所有少尿型肾衰竭儿童均使用了透析,而非少尿型肾衰竭儿童均未使用。少尿型组HUS诊断后的住院中位时间为12天,非少尿型组为6天。

结论

在大肠杆菌O157:H7感染期间,早在HUS发生之前尽早识别并进行胃肠外补液扩容,与减轻肾损伤衰竭相关。对于可能感染大肠杆菌O157:H7的儿童,在出现血性腹泻且培养结果未出时进行胃肠外补液,这一做法可在重要的HUS前间隔期加速补液扩容的开始。微生物学家对粪便进行大肠杆菌O157:H7的快速检测并立即报告推定阳性结果,可提醒医生患者有发生HUS的风险,并促使对尚未接受补液治疗的儿童进行补液扩容。我们的数据还表明,等渗静脉溶液作为维持液可能优于低渗液。感染大肠杆菌O157:H7并接受静脉补液扩容的儿童需要仔细监测。随着HUS的发展,这种监测应更加严格。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验